Summary
50 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: $247.0M against $10.1M.
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 23 USD is left as free cash.
- It bought back its own shares for $148.3M in the last fiscal year, 10% of its market value.
What to watch
- Earnings per share fell by 22% a year over the last 3 years.
- Operating profit covers the interest on its debt only 2.3 times.
- It earns only 3.3 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 38.5 USD for 1 USD of yearly profit. Over the last five years it was 96.5 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 2.9% a year. For the next fiscal year analysts expect revenue to grow by 3.8%. Earnings per share fell by 22% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 16 USD
- Research and development 16 USD
- Sales and administration 63 USD
- Taxes and other -0.5 USD
- Net profit 5.1 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10.0 USD
Out of every 100 USD of revenue, 5.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 11
- Hold 22
- Sell 3
Today's price within the analysts' price targets
The average target of $31.6 is 13% below today's price. 31% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 51%
- EXPAREL 40%
- ZILRETTA 8.2%
- Bupivacaine Liposome Injectable Suspension 0.5%
By region
The company reports no revenue by region.
Product brings in 51% of revenue. ZILRETTA grew fastest, by 74% a year.
Segments in detail